U.S. FTC approves Hikma deal for Custopharm with conditions
WASHINGTON – Generic drug maker Hikma Pharmaceuticals has won U.S. antitrust approval to buy Custopharm, Inc on condition that it divest an injectable steroid, the U.S. Federal Trade Commission said…